CIBC Private Wealth Group LLC Lowers Stock Position in Natera, Inc. (NASDAQ:NTRA)

CIBC Private Wealth Group LLC decreased its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 30.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,618 shares of the medical research company's stock after selling 4,737 shares during the period. CIBC Private Wealth Group LLC's holdings in Natera were worth $1,681,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its position in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc raised its stake in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares during the last quarter. Principal Securities Inc. boosted its stake in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC grew its holdings in Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several brokerages have issued reports on NTRA. Barclays began coverage on Natera in a research report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 target price for the company. BTIG Research reissued a "buy" rating on shares of Natera in a research note on Friday, February 28th. Royal Bank of Canada started coverage on shares of Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective for the company. StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. Finally, Sanford C. Bernstein boosted their price target on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and an average price target of $178.12.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the firm's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $140.48, for a total value of $421,440.00. Following the completion of the transaction, the insider now owns 141,782 shares in the company, valued at approximately $19,917,535.36. The trade was a 2.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 325,922 shares of company stock valued at $51,603,664. 7.60% of the stock is currently owned by corporate insiders.

Natera Trading Up 0.5 %

NASDAQ:NTRA traded up $0.63 during trading hours on Tuesday, reaching $138.89. 345,205 shares of the stock were exchanged, compared to its average volume of 1,377,036. The business has a 50-day moving average of $156.27 and a two-hundred day moving average of $151.65. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a market capitalization of $18.78 billion, a price-to-earnings ratio of -78.93 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.